Jeena Varghese1, Mouhammed Amir Habra. 1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: To present an update on the management of and future directions in adrenocortical carcinoma (ACC). RECENT FINDINGS: ACC is a rare malignancy with high morbidity and mortality. Surgery remains the mainstay treatment for localized disease, but it is often not feasible in more advanced cases. There is an ongoing controversy about the routine use of adjuvant treatments after surgery. Hormonal overproduction can complicate the management and worsen the prognosis of the disease. Systemic therapy with multiple cytotoxic drugs is often combined with the adrenolytic agent mitotane. Genomic analyses of ACC revealed numerous signal transduction pathway aberrations (insulin-like growth factor 2 overexpression, TP53 mutations and Wnt/β-catenin pathway activation), but so far, there has been no clinically meaningful breakthrough in targeting these genes. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in ACC is being explored in multiple ongoing trials. SUMMARY: Surgery by experienced team is the key treatment for localized ACC, whereas currently used chemotherapy has limited efficacy in advanced ACC. The improved understanding of the molecular pathways involved in ACC has not been translated into effective therapy. The development of new therapies requires collaborative effort to fight this disease.
PURPOSE OF REVIEW: To present an update on the management of and future directions in adrenocortical carcinoma (ACC). RECENT FINDINGS: ACC is a rare malignancy with high morbidity and mortality. Surgery remains the mainstay treatment for localized disease, but it is often not feasible in more advanced cases. There is an ongoing controversy about the routine use of adjuvant treatments after surgery. Hormonal overproduction can complicate the management and worsen the prognosis of the disease. Systemic therapy with multiple cytotoxic drugs is often combined with the adrenolytic agent mitotane. Genomic analyses of ACC revealed numerous signal transduction pathway aberrations (insulin-like growth factor 2 overexpression, TP53 mutations and Wnt/β-catenin pathway activation), but so far, there has been no clinically meaningful breakthrough in targeting these genes. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in ACC is being explored in multiple ongoing trials. SUMMARY: Surgery by experienced team is the key treatment for localized ACC, whereas currently used chemotherapy has limited efficacy in advanced ACC. The improved understanding of the molecular pathways involved in ACC has not been translated into effective therapy. The development of new therapies requires collaborative effort to fight this disease.
Authors: Dipika R Mohan; Antonio Marcondes Lerario; Tobias Else; Bhramar Mukherjee; Madson Q Almeida; Michelle Vinco; Juilee Rege; Beatriz M P Mariani; Maria Claudia N Zerbini; Berenice B Mendonca; Ana Claudia Latronico; Suely K N Marie; William E Rainey; Thomas J Giordano; Maria Candida B V Fragoso; Gary D Hammer Journal: Clin Cancer Res Date: 2019-02-15 Impact factor: 12.531
Authors: Hao Xie; Jun Yin; Manisha H Shah; Michael E Menefee; Keith C Bible; Diane Reidy-Lagunes; Madeleine A Kane; David I Quinn; David R Gandara; Charles Erlichman; Alex A Adjei Journal: Invest New Drugs Date: 2019-06-06 Impact factor: 3.850
Authors: Johannes Baur; Tjark-Ole Büntemeyer; Felix Megerle; Timo Deutschbein; Christine Spitzweg; Marcus Quinkler; Peter Nawroth; Matthias Kroiss; Christoph-Thomas Germer; Martin Fassnacht; Ulrich Steger Journal: BMC Cancer Date: 2017-08-04 Impact factor: 4.430
Authors: Rosa Maria Paragliola; Francesco Torino; Giampaolo Papi; Pietro Locantore; Alfredo Pontecorvi; Salvatore Maria Corsello Journal: Eur Endocrinol Date: 2018-09-10